HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

Biogen filing reveals Apellis deal details; Telix raises $600M

Inside Biogen's $5.6B buyout: CEO Chris Viehbacher has carried on with diversifying Biogen's business beyond its legacy of high-risk bets in neurology. After paying $7.3 billion for Reata in 2023, Biogen

By Endpoints News · Apr 15, 2026 · via Endpoints News
Biogen filing reveals Apellis deal details; Telix raises $600M

Image: Endpoints News

Tags
dealsformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
In industry's latest OTC pivot, Daiichi Sankyo lines up $1.5B consumer health unit sale to beverage giant Suntory
DealsFiercePharma ↗
In industry's latest OTC pivot, Daiichi Sankyo lines up $1.5B consumer health unit sale to beverage giant Suntory
With Daiichi Sankyo’s priorities increasingly tied to its innovative medicines—and its oncology portfolio in p…
Apr 17, 2026
UCB Buys Neurona for $650M, Bets on Regenerative Medicine and Epilepsy Cell Therapy
DealsBriefing
UCB Buys Neurona for $650M, Bets on Regenerative Medicine and Epilepsy Cell Therapy
UCB’s $650M-plus purchase of Neurona Therapeutics signals a move beyond small molecules into regenerative neur…
Apr 17, 2026
Novo Nordisk Bets on OpenAI to Accelerate Drug Development
DealsBriefing
Novo Nordisk Bets on OpenAI to Accelerate Drug Development
Novo Nordisk unveiled a global AI collaboration with OpenAI, extending from drug discovery to manufacturing as…
Apr 17, 2026